Ali Behbahani
CIK 1613867 · last filed 2026-07-06
Ali Behbahani is a corporate insider who has filed 142 SEC Form 4 insider transactions across 25 companies since 2014. The most recent filing, for GLUE, was dated Jul 6, 2026. Across all open-market trades the lifetime net is +$216.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $3.65B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.65B
25
142
$216.94M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GLUE | Director | 0 | $22.04 | $0 | $19.95M | 8 | 2026-07-06 |
| BDTX | Director | 4,551,286 | $1.76 | $8.01M | $20.20M | 29 | 2026-06-29 |
| NKTX | Director | — | $2.22 | — | $0 | 7 | 2026-06-11 |
| KRRO | Director | 1,297,893 | $10.50 | $13.63M | $0 | 5 | 2026-06-11 |
| CRSP | Director | 270 | $47.55 | $12.8K | $0 | 11 | 2026-06-09 |
| Arcellx, Inc. (ACLX) Delisted | Director | 0 | $115.07 | $0 | $0 | 7 | 2026-04-28 |
| SGP | Director | 2,989,408 | $21.62 | $64.63M | $15.00M | 2 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 674,554 | $16.35 | $11.03M | $34.97M | 8 | 2025-10-06 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 14,671,794 | $0.06 | $849.5K | $4.77M | 8 | 2025-08-19 |
| NeueHealth, Inc. (NEUE) Delisted | 10%+ Owner | — | $6.75 | — | $0 | 2 | 2024-10-03 |
| MBX | 10%+ Owner | 3,114,486 | $60.06 | $187.06M | $8.00M | 1 | 2024-09-17 |
| CVRX | Director | 316 | $4.95 | $1.6K | $0 | 6 | 2024-06-07 |
| SVRA | 10%+ Owner | 24,471,264 | $5.33 | $130.43M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 0 | $112.23 | $0 | $6.75M | 2 | 2023-06-15 |
| Oyster Point Pharma, Inc. (OYST) Delisted | Director | 3,573 | $11.17 | $39.9K | $0 | 4 | 2023-01-04 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| MINERVA SURGICAL INC (UTRS) Delisted | Director | 2,914 | $0.00 | $0 | $0 | 2 | 2022-06-14 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 0 | $0.00 | $0 | $21.03M | 9 | 2022-05-26 |
| TRVI | 10%+ Owner | 10,421,428 | $18.43 | $192.07M | $31.80M | 4 | 2022-04-13 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,563,257 | $0.49 | $1.27M | $9.51M | 2 | 2021-12-27 |
| MRKR | 10%+ Owner | 1,071,428 | $1.18 | $1.26M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
| ASND | Director | 12,000,000 | $254.44 | $3.05B | $20.00M | 5 | 2019-07-03 |
| NEVRO CORP (NVRO) Delisted | Director | 5,390 | $5.84 | $31.5K | $0 | 8 | 2018-05-23 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | — | — | — | $0 | 2 | 2017-06-02 |
Recent Filings
142 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | GLUE | Other (J) | −1,000,000 | $0 | EDGAR |
| 2026-06-29 | BDTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-22 | BDTX | Grant (A) | +8,961 | $14.9K | EDGAR |
| 2026-06-12 | GLUE | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | KRRO | Grant (A) | — | $0 | EDGAR |
| 2026-06-11 | NKTX | Grant (A) | — | $0 | EDGAR |
| 2026-06-09 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2026-04-28 | Arcellx, Inc. (ACLX) Delisted | Mixed | −4,631 | $0 | EDGAR |
| 2026-03-20 | BDTX | Grant (A) | +6,919 | $14.9K | EDGAR |
| 2026-03-12 | KRRO | Grant (A) | +207,100 | $2.30M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.